Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospital price data updated

This article was originally published in The Gray Sheet

Executive Summary

CMS updates hospital-specific volume and payment data for 31 common inpatient procedures on its 1Web site June 21. Intended to increase transparency for consumers, data on the procedures was first posted last June (2"The Gray Sheet" June 5, 2006, In Brief). According to the update, in fiscal year 2006 the midrange of payments for implantable defibrillator implants with cardiac catheterization was $37,102-$48,790, and charges averaged $135,717. For major joint replacements, the payment range was $10,085-$12,257 with average charges of $38,447. CMS plans to update the data for common outpatient, ambulatory surgical center and physician services later this summer and fall...

You may also be interested in...



Hospital price data published

CMS posts payment information on its website for the 30 most common elective procedures and reasons for admissions, including implantation of defibrillators and hip and knee replacements. Posted June 1 to kick off the agency's transparency initiative, the data shows the service volumes and Medicare payment ranges for all hospitals by county to help consumers compare price and quality of care (1"The Gray Sheet" March 20, 2006, p. 13). The agency plans to add geographically based payment information for ambulatory surgery centers this summer, and outpatient and physician services in the fall...

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel